HC Wainwright Estimates Harrow’s Q2 Earnings (NASDAQ:HROW)

Harrow, Inc. (NASDAQ:HROW) – Analysts at HC Wainwright reduced their Q2 2026 EPS estimates for shares of Harrow in a research note issued to investors on Thursday, May 14th. HC Wainwright analyst Y. Chen now anticipates that the company will earn $0.01 per share for the quarter, down from their prior forecast of $0.10. HC Wainwright has a “Buy” rating and a $70.00 price objective on the stock. The consensus estimate for Harrow’s current full-year earnings is $0.37 per share. HC Wainwright also issued estimates for Harrow’s Q4 2026 earnings at $0.61 EPS, FY2026 earnings at $0.15 EPS, Q1 2027 earnings at ($0.43) EPS, Q2 2027 earnings at ($0.03) EPS, Q3 2027 earnings at $0.40 EPS, Q4 2027 earnings at $1.06 EPS and FY2027 earnings at $1.14 EPS.

Harrow (NASDAQ:HROW) last posted its quarterly earnings data on Monday, May 11th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.31). The firm had revenue of $44.20 million during the quarter, compared to analysts’ expectations of $52.43 million. Harrow had a negative net margin of 5.57% and a positive return on equity of 19.59%. During the same period in the previous year, the company earned ($0.38) earnings per share.

A number of other equities analysts have also recently weighed in on the stock. Weiss Ratings cut shares of Harrow from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Wednesday, April 22nd. B. Riley Financial reissued a “buy” rating and issued a $65.00 price objective (down from $74.00) on shares of Harrow in a research report on Tuesday, April 7th. Wall Street Zen cut shares of Harrow from a “hold” rating to a “sell” rating in a research report on Saturday. Nomura cut shares of Harrow to a “neutral” rating in a research report on Wednesday, March 18th. Finally, Cantor Fitzgerald cut their target price on shares of Harrow from $91.00 to $88.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $69.43.

Harrow Stock Performance

NASDAQ:HROW opened at $30.90 on Tuesday. The company has a debt-to-equity ratio of 10.30, a current ratio of 2.48 and a quick ratio of 2.30. The firm has a 50-day moving average of $36.41 and a two-hundred day moving average of $42.11. The stock has a market cap of $1.15 billion, a P/E ratio of -75.36 and a beta of 0.34. Harrow has a 1-year low of $25.21 and a 1-year high of $54.85.

Institutional Investors Weigh In On Harrow

Institutional investors have recently modified their holdings of the stock. Blackhawk Capital Partners LLC acquired a new stake in shares of Harrow in the 3rd quarter valued at about $5,272,000. Penn Capital Management Company LLC acquired a new stake in Harrow during the third quarter worth about $15,717,000. Luxor Capital Group LP acquired a new stake in Harrow during the third quarter worth about $14,807,000. Lumbard & Kellner LLC acquired a new stake in Harrow during the third quarter worth about $4,281,000. Finally, New York State Common Retirement Fund raised its stake in Harrow by 1,944.7% during the third quarter. New York State Common Retirement Fund now owns 213,789 shares of the company’s stock worth $10,300,000 after acquiring an additional 203,333 shares during the period. Institutional investors and hedge funds own 72.76% of the company’s stock.

Insider Activity

In related news, CFO Andrew R. Boll bought 3,500 shares of the business’s stock in a transaction dated Thursday, May 14th. The shares were acquired at an average price of $29.90 per share, for a total transaction of $104,650.00. Following the purchase, the chief financial officer owned 814,679 shares in the company, valued at $24,358,902.10. This trade represents a 0.43% increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Company insiders own 12.80% of the company’s stock.

About Harrow

Harrow Health, Inc (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders.

Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives.